



Avra Medical Robotics, Inc.

Ticker OTCQB: AVMR

Page 1 of 2

Corporate Profile

as of October 11, 2018

Avra Medical Robotics, Inc. (“Avra”, “Avra Medical”, or the “Company”) (OTCQB: AVMR) founded in 2015 and located in Orlando, Florida, is a developmental stage medical device and technology company focused on creating intelligent surgical robotic systems. CEO, Chairman and Founder, Barry F. Cohen, leads Avra in developing an autonomous intelligent surgical robotic system platform, initially to be used for dermatology and medical aesthetic uses. Further research and development activities followed by regulatory approvals could lead to broader future medical uses of the Avra surgical robotic system platform in performing other minimally invasive surgeries autonomously or semi-autonomously. Avra’s objective is to produce safe, affordable and smaller autonomous surgical robotic systems that can be used not only in hospitals, but clinics and medical offices for minimal and non-invasive medical surgical procedures. Avra’s intelligent surgical robotic system will allow doctors to deliver a more consistent, precise and predictable patient outcome than is available with current methods. In addition to surgeon reported benefits of robotic surgeries, patients report that robotic surgery offers improved recovery times, less pain, and better outcomes over traditional open surgery performed directly with human hands

The Company is collaborating with the University of Central Florida in a multi-year contract to develop its initial prototype of the robotic system including the controlling software. The robotic system is planned for use initially for dermatology and skin resurfacing procedures, such as microneedling, injections and laser therapies. However, once the Food and Drug Administration (“FDA”) approvals are granted for these uses, Avra can seek regulatory approvals for other medical applications for its intelligent robotic system. The Company plans to initially target the large aesthetics and dermatology markets which currently include solutions such as Botox® and CO2 Lasers that are utilized for keratosis removal and for the treatment of lines, scarring, discoloration and other skin-related problems. Phase 2 research and development activities will address targeted drug delivery and other internal procedures that can benefit from Avra’s advanced intelligence guidance system.

The way robots and humans interact during medical care will change with Avra’s technology. Currently, robot-assisted surgery is by master/slave systems in which the surgeon manually controls the robot arms and its instruments remotely through a console. The Avra surgical robotic system is being designed for the surgeon to customize the procedure for each patient, then perform a full robotic simulation prior to the actual procedure which can then be performed autonomously or semi-autonomously using the Avra surgical robot arm. This practice will allow for consistently optimal results for both surgeons and patients.

Avra’s intelligent robotic system features facial mapping functions using the instrument guidance system (IGS) so tissue irregularities can be located in order to precisely place the microneedling or appropriate instrument with far greater accuracy than human, hand-held medical devices. The Avra surgical robotic system is designed to be compatible with FDA approved surgical instruments such as microneedling and laser units.

Avra’s intelligent surgical robotic system and its medical uses are part of patent pending technologies described in its U.S. and international patent applications. The patent applications describe an intelligent surgical robotic system that also includes methods of use and a navigation system. Avra’s intellectual property portfolio also includes proprietary software and design patent applications. The Company is the sole owner of its intellectual property, including proprietary navigation algorithms and software embodiments, which were developed in part by employees of the University of Central Florida.


According to a recent report by Grand View Research, the global aesthetic lasers annual market was valued at \$508 million dollars and is expected to grow at a compounded annual growth rate (“CAGR”) of 15.5%. Total expenditures on cosmetic surgeries in 2015 were \$12 billion dollars in the U.S.. The use of robotics is expected to be driven by the growing incidence rate of skin disorders and the new technologies to treat them.



AVRA Medical Robotics Technology

Sector: Healthcare
Industry: Medical Devices and Technology

Website: www.avramedicalrobotics.com



Avra Medical Robotic Arm

Recent Highlights

- Avra Medical is developing an intelligent surgical robotic system platform which will allow surgeons to simulate a medical procedure and review it prior to the actual procedure. The system allows surgeons to more precisely deploy surgical devices to deliver improved outcomes for patients
- Avra Medical is developing its system initially for applications in dermatology and aesthetic uses for the skin and other organ biopsy procedures.
- Avra Medical is managed and advised by a prestigious team of business experts, medical doctors, surgeons, and scientists. Avra is collaborating with the University of Central Florida, the largest university in the United States, for continued research and development activities related to software and electronics used in the intelligent robotic system.
- Avra Medical filed an S-1 Registration Statement with the SEC, which became effective on July 31, 2017. The Company is a public company with its shares trading on the OTCQB Market with the symbol AVMR.

Corporate Contact Information

Avra Medical Robotics, Inc.
Barry Cohen, CEO
3259 Progress Dr., Suite, 112
Orlando, FL 33826
Phone: 866-205-4430
www.avramedicalrobotics.com



Avra Medical Robotics, Inc.

Ticker OTCQB: AVMR

Page 2 of 2

Corporate Profile

as of October 11, 2018

Sector: Healthcare
 Industry: Medical Devices & Technology
 Website: www.avramedicalrobotics.com

Transparency Market Research states that the global skin care devices market is expected to grow at a 10.1% CAGR and will reach a potential value of \$10.7 billion by 2018. The Markets and Markets Research firm projects the medical robotics market to reach \$12 billion with a major segment being non-invasive surgery. According to the International Agency for Research on Cancer, WHO, the global incidence of cancer (excluding non-melanoma skin cancer) in 2012 amounted to 14.1 million. This incidence rate is expected to reach 23.6 million by 2030. Growth in prevalence clearly indicates a rise in the number of procedures.

Growing demand for minimally invasive surgery creates a market opportunity for the Avra intelligent surgical robotic system platform. Minimally invasive procedures result in fewer traumas to the patient and quicker recovery than invasive or open surgical procedures which is expected to fuel industry growth for surgical robotic systems.

Key players in the global medical robots market include Intuitive Surgical, Inc. (NASDAQ:ISRG), manufacturer of the da Vinci® robot; Stryker Corporation (NYSE:SYK); and Hansen Medical in the U.S. In the international arena, Hocoma AG in Switzerland as well as Mazor Robotics (NASDAQ:MZOR) in Israel are two major leading medical robotics firms who provide devices for image guided surgery and computer assisted surgery for orthopedics. Market caps of these U.S. and international companies range from \$1.53 billion to \$61.8 billion. The major participants in the medical robotics industry are medical device companies, hospitals and diagnostic centers, ambulatory surgery centers, and medical spas.

Avra Medical is an FDA registered company and has begun the regulatory approval process. The Company will meet with the FDA for a preliminary assessment of its intelligent surgical robotic system, and if directed, will then go through a clinical trial procedure to determine the efficacy and safety of its medical device. Since the Avra intelligent surgical robotic system will be incorporating instruments that are already approved by the FDA, it is possible that Avra's system could be deemed "substantially equivalent" in safety and effectiveness to another lawfully marketed device. As long as the device is used for a similar purpose that has been approved, the device should clear the FDA much faster than approving a new device with a new use. This path should also allow the Company to more quickly obtain FDA approvals should it seek approval in the future for other uses of the robotic system such as a targeted drug delivery system for example.

The Avra Medical Management team includes: Barry F. Cohen, Founder, Chief Executive Officer and Chairman; Ray Powers, Ph.D., Chief Operating Officer; Farhan Taghizadeh, M.D., Chief Medical Officer; Nicole Bergman-Fong, J.D., Corporate Counsel; Peter Carnegie, Director; A. Christian Schauer, Director; and Nikhil Lalit Shah, DO, MPH, Chief Strategy Officer. Members of Avra Management team and its Medical Advisory Board consist of top medical practitioners at highly rated medical and research institutions with many among the top surgeons utilizing surgical robotics globally.

The Avra Medical Advisory Board includes Vipul Patel, M.D., Medical Director of the Global Robotics Institute at Florida Hospital and Founder of the Society of Robotic Surgery. Dr. Patel has personally performed the most robotic surgeries in the world with over 11,000 robotic prostatectomies. Dr. Patel is also a professor at the UCF College of Medicine. Other Avra Medical Advisory Board members include Juan Jose Badimon, Ph.D., Professor of Medicine and Director of the Atherothrombosis Research Unit at the Cardiovascular Institute of Mount Sinai School of Medicine in New York; Yuman Fong, M.D., an internationally known expert in cancer and sought-after consultant on a wide range of medical robotic research; Hiep Nguyen, M.D., who is a world-renowned pediatric urologist who specializes in robotic surgeries; and Dr. Jochen Binder, Priv. Doz. Dr. med., recognized as the world's first surgeon to utilize the da Vinci® system for prostate surgery; and Heywood Y. Epstein, M.D. With this strong team, Avra is well prepared to expand rapidly.

On September 7, 2018, the Company was approved to begin trading its shares on the OTCQB exchange. There are currently 20.99 million shares issued and outstanding with approximately 3.97 million shares in the float as of September 30, 2018. The Company is seeking additional financing in order to meet working capital needs and to seek FDA approval. Based upon the market cap of other leading industry medical robotic participants, ranging from \$1.9 billion to \$59 billion, it is believed that Avra Medical Robotics, Inc. could see a substantial increase in value when (1) its FDA approval is granted, and/or (2) when its core patents issue. A strategic industry investment similar to what recently occurred with Medtronic's (NYSE:MDT) investment into Mazor Robotics Ltd. (NASDAQ:MZOR) may also help the Company's stock price rise when considering Avra's technology and planned product developments. It may only be a matter of time before the valuation gap between Avra's current market cap and these industry comps (lowest is \$1.53 billion) narrows. The Company's innovative technology offers strong potential to revolutionize robotic surgeries. Avra Medical's new intelligent surgical robotic platform, when commercially available, is poised to significantly enhance patient and physician demand through improved results which, if widely adopted, would be beneficial to the Company's revenue growth in the near future.

Income Statement	YE 2016	YE 2017	Balance Sheet	YE 2016	YE 2017	Cash Flow Statement	YE 2016	YE 2017
Revenue	\$ -	-	Cash & cash equivalents	248,219	452,572	Operating Cash Flow	(211,944)	(446,856)
R & D	127,578	71,170	Total Assets	292,232	509,962	Investing Cash Flow	(43,548)	(4,174)
SG&A	334,915	939,637	Current Liabilities	647,292	408,869	Financing Cash Flow	503,611	655,383
Net Loss	(484,982)	(1,037,723)	Total Shareholder's Equity	(355,060)	101,093	Cash at end of period	248,219	452,572

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$5000 in cash to Alan Stone & Company LLC for preparation and distribution of this updated profile, plus other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.